Fig. 8: Graphical summary of the present study. | Nature Communications

Fig. 8: Graphical summary of the present study.

From: YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

Fig. 8

a YAP1 was activated when ALK-rearranged cancer cells survived a treatment with ALC. Combinatorial therapy against ALK and YAP1 may achieve complete remission in treatment naïve ALK-rearranged tumors. b A mechanism underlying initial survival against ALC. YAP1 is activated by ALC. Activated YAP1 enters the nucleus and promotes the expression of BCLXL and MCL1. MCL1 and Bcl-xL inhibit apoptosis. Verteporfin inhibits the promoter activity of YAP1, as reported previously.

Back to article page